References
- 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 (PMID: 7382552).
- 2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
- 3. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46:1387–13911768547210.1002/hep.21827
- 4. Cortez-Pinto H, Camilo ME, Baptista A, et al. Nonalcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–358.10.1016/S0261-5614(99)80015-6
- 5. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011;60:2011-7.21788578
- 6. Reilly ML, Schillie SF, Smith E, et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. J Diabetes Sci Technol 2012;6:858–866.10.1177/193229681200600417
- 7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285.
- 8. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889.
- 9. Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-477510.3748/wjg.14.4771
- 10. Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. (2017) Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study.28350839
- 11. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. AmJ Med 2007; 120: 829-834.
- 12. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1095-110510.1097/00042737-200411000-00003
- 13. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. AmJ Gastroenterol 2006; 101: 70-75
- 14. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725
- 15. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. AmJ Gastroenterol 2006; 101: 70-75.
- 16. Giovanni Targher1, Amedeo Lonardo2, Christopher D. Byrne et al. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus, doi: 10.1038/nrendo.2017.173.10.1038/nrendo.2017.173
- 17. Mark CC Cheah, Arthur J McCullough and George Boon-Bee Goh. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017 Sep 28; 5(3): 261–271.
- 18. Haixia Liu, Jing Fu Ruixia Hong et al. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. PLoS One. 2015; 10(7): e0127782.
- 19. Adams LA, Waters OR, Knuiman MW, et al. NAFLDas a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. AmJ Gastroenterol 2009;104:861-7.
- 20. Xiong G L, Gadde K M. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med 2014;126:110-6.10.3810/pgm.2014.03.2746
- 21. Brashier DB, Sharma AK, Dahiya N, et al. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother 2014;5:175-8.
- 22. Caixàs A, Albert L, Capel I, et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014;8:1419-27.
- 23. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010;33:284-6.10.2337/dc09-0148
- 24. Horlander J, Kwo P, Cummings O. Atorvastatin for the treatment of NASH (Abstract). Gastroenterol 2001;5:A- 544.
- 25. Arun J. Sanyal, M.D. et al, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, N Engl J Med. 2010 May 6; 362(18): 1675–1685. doi:10.1056/NEJMoa 0907929.10.1056/NEJMoa0907929